TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)

Summary

The study purpose is to establish the safety and tolerability of IMA201 in patients with solid tumors that express melanoma-associated antigen 4 and/or 8 (MAGEA4/8).

Timeline

Start

2018-12-19

Primary completion

2023-04-20

Completion

2023-09-18

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “The combined data readout during early phases of dose escalation for the ACTengine ® programs, IMA201, IMA202 and IMA203, indicated first anti-tumor activity” immatics.com ↗

Publications

• Fritsche J, Rakitsch B, Hoffgaard F, Romer M, Schuster H, Kowalewski DJ, Priemer M, Stos-Zweifel V, Horzer H, Satelli A, Sonntag A, Goldfinger V, Song C, Mahr A, Ott M, Schoor O, Weinschenk T. Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection. Proteomics. 2018 Jun;18(12):e1700284. doi: 10.1002/pmic.201700284. Epub 2018 Apr 10.

Drugs

Indications